Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of a comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis (RRMS)

Trial Profile

Study of a comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis (RRMS)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 May 2018

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab (Primary) ; Dimethyl fumarate; Glatiramer acetate; Interferon beta; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 May 2018 New trial record
    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top